141256-52-2

Basic information

• Product Name: MATRILYSIN
• Synonyms: Anti-MMP-7, C-Terminal antibody produced in rabbit;Pump-1 protease;Uterine metalloproteinase;PUMP-1;PUMP-1, ACTIVE, HUMAN, RECOMBINANT;RHMMP-7;RHMMP-7, ACTIVE;MMP-7
• CAS NO: 141256-52-2
• Product Categories: enzyme
• Mol File: 141256-52-2.mol
• Article Data: 0

Chemical Properties

• Appearance: /buffered aqueous solution
• Storage Temp.: −70°C
• CAS DataBase Reference: MATRILYSIN(CAS DataBase Reference)
• NIST Chemistry Reference: MATRILYSIN(141256-52-2)
• EPA Substance Registry System: MATRILYSIN(141256-52-2)

Safety Data

• Hazard Codes: B
• WGK Germany: 3
• Hazardous Substances Data: 141256-52-2(Hazardous Substances Data)

Usage

Uses

Matrix metalloproteinase-7 (MMP7) human has been used in in silico analysis of MMP-7 proteolysis of perlecan.

General Description

Matrix metalloproteinase-7 (MMP7) also referred to as matrilysin is encoded by the gene mapped to human chromosome 11q21-q22. MMP7 is a smallest member of MMP enzyme family and is highly expressed in cancer cells. MMP7 is exclusively released by epithelial cells.

Biochem/physiol Actions

Matrix metalloproteinase-7 (MMP-7) catalyzes the cleavage of extracellular matrix (ECM) proteins such as proteoglycans, fibronectin, entactin, laminin, collagen III/ IV/ V/ IX/ X/ XI, type I/ II/ IV/ V gelatins, and elastin. Matrix metalloproteinase-7 facilitates initial stages of tumor progression. Activated MMP7 plays a vital role in human colorectal cancer (CRC) liver metastases. Overexpression of MMP7 is observed in various human cancers, such as breast, lung, prostate, esophagus, stomach, endometrium, and ovarian carcinomas, as well as esophageal squamous cell carcinomas. Increased expression of MMP7 is also associated with pathogenesis of demyelinating multiple sclerosis (MS) lesions. Both in silico and in vitro studies show that MMP7 degrades glycosylated and basement membrane bound perlecan and plays a vital role in prostate cancer cell invasion.